Skip to main content

Table 1 Composite prevalence estimates when the “true” underlying type-specific infection burden is pre-specified as the reported prevalence in the U.S.

From: Evaluation of using composite HPV genotyping assay results to monitor human papillomavirus infection burden through simulation

No. of HPV types*

Time§

Pre-specified true composite prevalence (SD)

Composite prevalence estimate (SD)

Est. to true ratio

Composite prevalence estimate (SD)

Est. to true ratio

Composite prevalence estimate (SD)

Est. to true ratio

Composite prevalence estimate (SD)

Est. to true ratio

a: Sensitivity ≤ Specificity

   

Sen.= 0.95

 

Sen. = 0.90

 

Sen. = 0.85

 

Sen. = 0.80

 

Spe.= 0.95

Spe. = 0.95

Spe. = 0.95

Spe. = 0.95

2

Baseline

0.064 (0.004)

0.151 (0.006)

2.359

0.148 (0.005)

2.313

0.146 (0.006)

2.281

0.143 (0.005)

2.234

 

Reduced

0.032 (0.003)

0.125 (0.005)

3.906

0.123 (0.005)

3.843

0.121 (0.005)

3.781

0.120 (0.005)

3.750

 

% red.

50

17.2

 

16.9

 

17.1

 

13.9

 

4

Baseline

0.120 (0.005)

0.275 (0.007)

2.292

0.269 (0.007)

2.242

0.264 (0.007)

2.200

0.260 (0.007)

2.167

 

Reduced

0.062 (0.004)

0.229 (0.007)

3.694

0.227 (0.006)

3.661

0.224 (0.007)

3.613

0.222 (0.006)

3.581

 

% red.

48

16.7

 

15.6

 

15.2

 

14.6

 

14

Baseline

0.282 (0.007)

0.616 (0.007)

2.184

0.609 (0.008)

2.160

0.603 (0.008)

2.138

0.596 (0.008)

2.113

 

Reduced

0.259 (0.007)

0.604 (0.008)

2.332

0.599 (0.008)

2.313

0.593 (0.008)

2.290

0.587 (0.008)

2.266

 

% red.

8.2

1.9

 

1.6

 

1.7

 

1.5

 

37

Baseline

0.617 (0.008)

0.904 (0.004)

1.465

0.900 (0.005)

1.459

0.895 (0.005)

1.451

0.891 (0.005)

1.444

 

Reduced

0.596 (0.008)

0.899 (0.005)

1.508

0.895 (0.005)

1.502

0.891 (0.005)

1.495

0.887 (0.005)

1.488

 

% red.

3.4

0.5

 

0.6

 

0.4

 

0.4

 

b: Sensitivity ≥ Specificity

   

Sen. = 0.95

 

Sen. = 0.95

 

Sen. = 0.95

 

Sen. = 0.95

 

Spe. = 0.95

Spe. = 0.90

Spe. = 0.85

Spe. = 0.80

2

Baseline

0.064 (0.004)

0.151 (0.006)

2.359

0.237 (0.007)

3.703

0.318 (0.007)

4.969

0.394 (0.008)

6.156

 

Reduced

0.032 (0.003)

0.125 (0.005)

3.906

0.213 (0.006)

6.656

0.297 (0.007)

9.281

0.374 (0.008)

11.688

 

% red.

50

17.2

 

10.1

 

6.6

 

5.1

 

4

Baseline

0.120 (0.005)

0.275 (0.007)

2.292

0.409 (0.008)

3.408

0.525 (0.008)

4.375

0.621 (0.008)

5.175

 

Reduced

0.062 (0.004)

0.229 (0.007)

3.694

0.374 (0.008)

6.033

0.496 (0.008)

8.000

0.598 (0.008)

9.645

 

% red.

48

16.7

 

8.6

 

5.5

 

3.7

 

14

Baseline

0.282 (0.007)

0.616 (0.008)

2.184

0.797 (0.006)

2.826

0.895 (0.005)

3.174

0.947 (0.004)

3.358

 

Reduced

0.259 (0.006)

0.604 (0.008)

2.332

0.792 (0.006)

3.058

0.892 (0.005)

3.444

0.945 (0.004)

3.649

 

% red.

8.2

1.9

 

0.6

 

0.3

 

0.2

 

37

Baseline

0.617 (0.008)

0.904 (0.004)

1.465

0.975 (0.002)

1.580

0.993 (0.001)

1.609

0.998 (0.007)

1.515

 

Reduced

0.596 (0.008)

0.899 (0.005)

1.508

0.974 (0.003)

1.634

0.993 (0.001)

1.666

0.998 (0.007)

1.674

 

% red.

3.4

0.5

 

0.1

 

0

 

0

 
  1. *2: high-risk vaccine types (HPV 16, 18); 4: vaccine types (HPV 6, 11, 16, 18); 14: high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68); 37: HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59,61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39).
  2. §Pre-specified type-specific prevalence at baseline: HPV 6 = 0.028, HPV11 = 0.034, HPV16 = 0.047, HPV18 = 0.019, HPV26 = 0.022, HPV31 = 0.015, HPV33 = 0.013, HPV35 = 0.023, HPV39 = 0.011, HPV40 = 0.018, HPV42 = 0.025, HPV45 = 0.020, HPV51 = 0.041, HPV52 = 0.036, HPV53 = 0.058, HPV54 = 0.038, HPV55 = 0.024, HPV56 = 0.023, HPV58 = 0.014, HPV59 = 0.030, HPV61 = 0.040, HPV62 = 0.065, HPV64 = 0.002, HPV66 = 0.034, HPV67 = 0.013, HPV68 = 0.016, HPV69 = 0.027, HPV70 = 0.020, HPV71 = 0.056, HPV72 = 0.012, HPV73 = 0.015, HPV81 = 0.027, HPV82 = 0.054, HPV83 = 0.041, HPV84 =0.048, HPV89 = 0.047, HPVIS39 = 0.014.
  3. Reduced: vaccine types (HPV 6, 11, 16, 18) are reduced 50%.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us